ProtectionSep 18 2018

The Exeter launches unlimited cancer cover

twitter-iconfacebook-iconlinkedin-iconmail-iconprint-icon
Search supported by
The Exeter launches unlimited cancer cover

Health insurer The Exeter has launched a private health insurance policy with a digital first approach.

The Health+ policy and corresponding HealthWise app have been designed in collaboration with specialist advisers, who wanted the control and flexibility to build the right policy for their clients, the insurer said.

Launched yesterday (17 September), the policy comprises of a core cover module, which includes unlimited cover for in-patients, day-patients and cancer treatment.

The cover offers optional excesses, with a choice of underwriting methods, giving advisers the ability to select premiums and work to a range of budgets.

The HealthWise app, launched in partnership with medical services network Square Health, will allow members to benefit from ‘e-treatments’ with instant access to a GP through the app.

Karen Woodley, head of sales at The Exeter, said: "At The Exeter we know how important it is that everyone has access to the healthcare they deserve, when they need it the most.

"We’ve taken a digital first approach to enable our customers to access the fastest possible diagnosis and best available treatment through their tablets and smartphones with the HealthWise app."

Alan Lakey, director at CIExpert, said: "Exeter is a valued brand and is seen as an insurer that works hard to design sensible and worthwhile products. Its claims record is excellent and it aims to please intermediaries as opposed to annoying them with pointless detail.

"This new product looks very good. Unlimited cancer cover is something that will resonate with many people. The link up with the excellent Square Health is also indicative of going that extra mile."

He added: "Having designed the plan with input from PMI specialists is another indication that they are empathetic as opposed to introducing plans based around committee decisions and poor and often flawed market research."